Skip to main content
OpenTrials
Completed

NCT Number: NCT05210569

Visual Outcomes of Vivity in Patients With High Axial Length

The objective is to assess the visual outcomes and quality of vision of patients receiving the AcrySof® Vivity Intraocular lens (IOL), when implanted in eyes with high ocular axial length (≥24.5mm), after uneventful cataract surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Image Plus Laser Eye Centre

Winnipeg, Manitoba, R3C4K5, Canada

About this study

This study is a single-arm unmasked clinical evaluation study of binocular uncorrected visual acuity at distance (6m), intermediate (66cm) and near (40cm), when implanted in eyes with high ocular axial length (≥24.5mm), after successful bilateral cataract surgery. Subjects will be assessed preoperatively, operatively, and at 1 day, 1 week, 1 month, and 3 months postoperatively. Clinical evaluations will include administration of a visual disturbance questionnaire (QUVID) and a satisfaction questionnaire (IOLSAT), as well as measurement of binocular and monocular visual acuities and manifest refraction.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Subjects are eligible for the study if they meet the following criteria:

Note: Ocular criteria must be met in both eyes.

Inclusion criteria

  • Undergoing uncomplicated bilateral cataract surgery with IOL implantation.
  • Gender: Males and Females.
  • Age: 50 years or older.
  • Willing and able to provide written informed consent for participation in the study.
  • Willing and able to comply with scheduled visits and other study procedures.
  • Motivated for greater degree of spectacle independence vs monofocal IOL.
  • Axial length ≥24.5mm in both eyes.
  • Planned cataract removal by femtosecond laser.

Exclusion criteria

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

  • Ocular comorbidity that might hamper postoperative visual acuity.
  • Previous refractive surgery.
  • Irregular corneal astigmatism.
  • Evidence of keratoconus as per Pentacam.
  • Expected post-op VA worse than 20/25 (Snellen).
  • Refractive lens exchange.
  • Difficulties comprehending written or spoken English language.
  • Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).
  • Clinically significant or severe ocular surface disease that would affect study measurements based on the investigator's opinion.
  • Axial length <24.5mm.
  • Evidence of macular pathology as per optical coherence tomography examination.

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

Treatment and study plan

Vivity

Device

Vivity intraocular lens (IOL)

Primary outcomes

  1. Binocular Uncorrected Distance Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Binocular uncorrected distance visual acuity (logMAR)

  2. Binocular Uncorrected Intermediate Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Binocular uncorrected intermediate visual acuity (logMAR)

  3. Binocular Uncorrected Near Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Binocular uncorrected near visual acuity (logMAR)

Secondary outcomes

  1. Prediction Error

    Time frame: 3 months postoperatively

    Percentage of eyes with absolute prediction error of 0.5D or less

  2. Binocular Corrected Distance Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Binocular corrected distance visual acuity (logMAR)

  3. Binocular Distance Corrected Intermediate Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Binocular distance corrected intermediate visual acuity (logMAR)

  4. Binocular Distance Corrected Near Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Binocular distance corrected near visual acuity (logMAR)

  5. Monocular Corrected Distance Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Monocular corrected distance visual acuity (logMAR)

  6. Monocular Distance Corrected Intermediate Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Monocular distance corrected intermediate visual acuity (logMAR)

  7. Monocular Distance Corrected Near Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Monocular distance corrected near visual acuity (logMAR)

  8. Manifest Refraction Spherical Equivalent

    Time frame: 3 months postoperatively

    Manifest refraction spherical equivalent

  9. Questionnaire

    Time frame: 3 months postoperatively

    Questionnaire for visual disturbance scores (QUVID)

  10. Percentage of Participants With Spectacle Independence

    Time frame: 3 months

    The Intraocular Lens Satisfaction questionnaire (IOLSAT). Subjects were asked how often they needed to wear eyeglasses to see at distance, intermediate, and near. The percentage was calculated as (# of subjects responding "Never" or "Rarely") divided by (# of subjects) times 100. A higher percentage is a better outcome.

  11. Binocular Distance-corrected Low Contrast Distance Visual Acuity (logMAR)

    Time frame: 3 months postoperatively

    Binocular distance-corrected low contrast distance visual acuity (logMAR)

Sponsors and collaborators

Lead sponsor

Dr. James J. Wiens Medical Corporation

Other

Collaborators

  • Sengi

Registry information

Official study title

Visual Outcomes of the AcrySof® Vivity Intraocular Lens in Patients With High Ocular Axial Length

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jan 27, 2022
Registry last updated
Mar 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.